Studies heart tissue in people with heart failure and preserved ejection fraction
Takes heart tissue samples to study changes in people with heart failure.
Key facts
- Who runs it
- Northwestern University
- Where
- Baltimore, Boston, Chicago, Philadelphia, Rochester, and Winston-Salem, United StatesSee the 6 sites
- Trial code
- Registry title
- Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 8 Nov 2024
- Expected to end
- Dec 2027
- Type of study
- Observational, 2 groups
- Record updated
- 29 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 30 or older who have heart failure with preserved ejection fraction, or who may have it. It looks at the heart tissue with a biopsy taken during a heart catheter test.
- Age
- 30 years or older
- Sex
- All sexes
- Disease stage
- Heart failure with a left ventricular ejection fraction of 50% or more, signs or symptoms of heart failure, and NYHA functional class II-IV. Confirmed HFpEF needs at least one more sign, such as raised BNP or NTproBNP, a past hospital stay for heart failure, or raised wedge pressure. Suspected HFpEF means none of these are met.
- Earlier treatment
- People on direct oral anticoagulants must stop them long enough for blood clotting to return to normal. People on warfarin must have an INR below 1.6.
- Biomarker or test result
- For confirmed HFpEF, BNP of 75 pg/ml or more, or NTproBNP of 225 pg/ml or more, in sinus rhythm. In atrial fibrillation or flutter, BNP of 225 pg/ml or more, or NTproBNP of 675 or more.
Main reasons for not taking part
- Pregnancy
- Active bleeding or a clotting disorder
- Platelet count below 50,000/ml
- Infection or fever
- Left bundle branch block
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- HFpEF criteria; Age ≥30 years; Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability); Definition of HFpEF: signs and/or symptoms of HF, NYHA functional class II-IV, and at least one of the following:; Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center; Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography); Previously documented elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise); Elevated H2FPEF score69 (≥5) or HFA-PEFF70 score (≥5); Suspected HFpEF criteria
- Age ≥30 years
- Left ventricular ejection fraction ≥50% measured by echocardiography, CMR or MUGA (measured within one year + clinical stability)
- Signs and/or symptoms of HF, NYHA functional class II-IV and all of the following:; Does not meet BNP or NT-proBNP criteria for HFpEF (above); No prior HF hospitalization meeting HF criteria (above); No previous hemodynamic catheterization documentation of HF (as above)
Who cannot take part
- 1. Inadequate echo or fluoroscopic images; Neck anatomy unfavorable for jugular venous cannulation; Therapy with direct oral anticoagulants without cessation for a period (age, renal function, and agent specific) deemed adequate to normalize coagulation according to local clinical guidelines; Previous or ongoing therapy with warfarin with INR ≥ 1.6 measured day before or of EMB; Platelet count < 50,000/ml; Active bleeding or coagulation disorder; Infection or fever; Endocarditis; Pregnancy; Intracardiac thrombus; RV Aneurysm; Clinically significant tricuspid, pulmonary or aortic valve stenosis; Tricuspid or pulmonary mechanical valve prosthesis; Left bundle branch block
Where in United States
- Johns Hopkins UniversityBaltimore, United StatesContact: Matt KauffmanTaking people
- Mass General BrighamBoston, United StatesContact: Diane Cocca-SpoffordTaking people
- Northwestern UniversityChicago, United StatesContact: Laura AlagnaTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Tiffany SharkoskiTaking people
- Mayo ClinicRochester, United StatesContact: Brendon UrenaTaking people
- Wake Forest UniversityWinston-Salem, United StatesContact: Ben NelsonTaking people
About the trial
What the trial wants to find out
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
The 2 groups in the trial
- HFpEF
Participants with HFpEF
- Non-HFpEF
Participants without HFpEF
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction (MM-HFpEF) A HeartShare Clinical Study
- Plain-language title
- Studies heart tissue in people with heart failure and preserved ejection fractionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 September 2026